Travere Therapeutics (TVTX) Q2 2026 earnings summary

Executive summary

• Achieved record commercial performance in Q2 2026, with FILSPARI U.S. net sales of $141.1M, up 96% year-over-year, driven by strong demand in both IgA nephropathy and a successful FSGS launch, with over 2,000 new patient start forms.

• FILSPARI is now approved and commercially available for both IgAN and FSGS, establishing itself as a foundational nephroprotective therapy with significant market runway and less than 10% market penetration.

• Expanded rare kidney disease pipeline through the exclusive licensing of civorebrutinib, a next-generation BTK inhibitor, with $112.5M upfront payment and potential for multiple immune-mediated indications.

• Advanced pegtibatinase program with ongoing pivotal Phase 3 HARMONY Study enrollment for HCU, topline data expected in 2H 2027.

• Strengthened balance sheet via convertible note refinancing, raising $158M net cash and supporting long-term growth.

Financial highlights

• Total U.S. net product sales reached $161.4M in Q2 2026, up strongly both sequentially and year-over-year.

• FILSPARI U.S. net product sales grew 96% year-over-year to $141.1M.

• Total revenue for the quarter was $169.6M, including $8.2M in licensing collaboration revenue.

• Ended Q2 with $489.2M in cash, equivalents, and marketable securities.

• GAAP R&D and SG&A expenses totaled $156.4M, including $22.2M in non-cash expenses; net loss for Q2 was $34.8M, with non-GAAP adjusted net loss of $9.0M.

Outlook and guidance

• Expect continued FILSPARI revenue growth in both FSGS and IgA nephropathy, supported by label expansion and evolving treatment guidelines.

• Full-year gross net discounts for FILSPARI anticipated in the mid 20% range.

• Topline results from the HARMONY Phase 3 study for pegtibatinase expected in 2H 2027.

• Plans to initiate a Phase 4 study for FILSPARI in FSGS patients of African ancestry in 2H 2026.

• No revision to the $3B peak annual FILSPARI sales estimate, but confidence in exceeding it remains high.